Breast Cancer Research and Treatment

, Volume 32, Issue 3, pp 301–310 | Cite as

Detection of prostate-specific antigen immunoreactivity in breast tumors

  • Eleftherios P. Diamandis
  • He Yu
  • Donald J. A. Sutherland
Report

Abstract

Prostate-specific antigen (PSA) is a glycoprotein produced by the epithelial cells of the prostate. PSA is currently used in clinical practice to facilitate diagnosis and monitoring of prostate carcinoma. The prostate is an organ that possesses androgen, estrogen, and progesterone receptors, and in this respect is similar to the breast. We postulated that breast tumors might also have the ability to produce PSA. We performed these studies on a collection of 525 tumor specimens collected for routine biochemical determination of estrogen and progesterone receptors. Using a highly sensitive immunofluorometric procedure, we measured the p53 tumor suppressor gene product and PSA. Twenty nine percent of the breast tumor extracts contained detectable levels of PSA immunoreactivity (> 0.05 µg/L). The immunoreactive PSA content was associated with estrogen and/or progesterone receptor-positive tumors (P < 0.002). No association was found between PSA immunoreactivity and levels of the p53 tumor suppressor gene product (P = 0.37). High performance liquid chromatography and Western blot analysis revealed that the PSA immunoreactivity in the tumor had a molecular weight of 30 kDa, similar to that of seminal PSA. Immunoreactive PSA-positive tumors were associated with younger women (P = 0.012) and earlier disease stage (P = 0.064). We postulate that PSA immunoreactivity may be an additional marker of steroid hormone receptor-ligand action.

Key words

breast cancer prognostic markers prostate specific antigen steroid hormone receptors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Carter HB, Coffey DS: The prostate: an increasing medical problem. The Prostate 16: 39–48, 1990Google Scholar
  2. 2.
    Nomura AMY, Kolonel LN: Prostate cancer: a current perspective. Am J Epidemiol 13: 200–227, 1991Google Scholar
  3. 3.
    Bruchovsky N, Brown EM, Coppin CM,et al.: The endocrinology and treatment of prostate tumor progression. Prog Clin Biol Res 239: 347–357, 1987Google Scholar
  4. 4.
    Thompson TC: Growth factors and oncogenes in prostate cancer. Cancer Cells 2: 345–354, 1990Google Scholar
  5. 5.
    Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907–923, 1991Google Scholar
  6. 6.
    Diamandis EP: Immunoassays with time-resolved fluorescence spectroscopy. Principles and applications. Clin Biochem 21: 139–150, 1988Google Scholar
  7. 7.
    Yu H, Diamandis EP: Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39: 2108–2114, 1993Google Scholar
  8. 8.
    Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer, (first of three parts). New Engl J Med 327: 319–328, 1992Google Scholar
  9. 9.
    Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer, (second of three parts). New Engl J Med 327: 390–398, 1992Google Scholar
  10. 10.
    Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer, (third of three parts). New Engl J Med 327: 473–480, 1992Google Scholar
  11. 11.
    McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. New Engl J Med 326: 1756–1761, 1992Google Scholar
  12. 12.
    McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary nodenegative breast cancer patients. J Natl Cancer Inst 82: 1006–1015, 1990Google Scholar
  13. 13.
    Muss HB: Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 21: 15–26, 1992Google Scholar
  14. 14.
    Hassapoglidou S, Diamandis EP, Sutherland DJA: Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. Oncogene 8: 1501–1509, 1993Google Scholar
  15. 15.
    Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostatespecific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222–226, 1991Google Scholar
  16. 16.
    Lilja H, Christensson A, Dahlen U,et al.: Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37: 1618–1625, 1991Google Scholar
  17. 17.
    Ford TF, Butcher DN, Masters JRW, Parkinson CM: Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. Br J Urol 57: 50–55, 1985Google Scholar
  18. 18.
    Papotti M, Paties C, Peveri V, Moscuzza L, Bussolati G: Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors. Bas Appl Histochem 33: 25–29, 1989Google Scholar
  19. 19.
    Slamon DJ, Clark GM, Wong SG,et al.: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182, 1987Google Scholar
  20. 20.
    Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer 54: 2436–2440, 1984Google Scholar
  21. 21.
    Wolf DA, Schulz P, Fittler F: Transcriptional regulation of prostate kallikrein-like gene by androgen. Mol Endocrinol 6: 753–762, 1992Google Scholar
  22. 22.
    Henttu P, Liao SS, Vihko P: Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA) but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. Endocrinology 130: 766–772, 1992Google Scholar
  23. 23.
    Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostate adenocarcinoma cell line, LNCaP. Prostate 21: 63–73, 1992Google Scholar
  24. 24.
    Weber JP, Oesterling JE, Peters CA, Partin AW, Chan DW, Walsh PC: The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostate hyperplasia. J Urol 141: 987–991, 1989Google Scholar
  25. 25.
    Wei LL: Transcriptional activation of the estrogen receptor. Clin Chem 39: 341–345, 1993Google Scholar
  26. 26.
    Milgrom E: The oestrogen-regulated pS2-BCEI protein in breast cancer. In: Goldhirsch A (ed) Endocrine Therapy of Breast Cancer V. Springer Verlag, Berlin, 1992, pp 17–22Google Scholar
  27. 27.
    Foekens JA, Rio MC, Seguin P,et al.: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990Google Scholar
  28. 28.
    Rochefort H: Cathepsin D in breast cancer. Breast Cancer Res Treat 16: 1–13, 1990Google Scholar
  29. 29.
    Silvestrini R, Veneroni S, Benini E, DiFronzo G, Daidone MG: p53 and cathepsin D are independent of established prognostic factors in breast cancer. Int J Oncol 1: 507–512, 1992Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Eleftherios P. Diamandis
    • 1
    • 3
  • He Yu
    • 1
    • 3
  • Donald J. A. Sutherland
    • 2
  1. 1.Department of Clinical BiochemistryThe Toronto Hospital, Toronto Western DivisionToronto, OntarioCanada
  2. 2.Toronto Bayview Regional Cancer CentreSunnybrook Medical Centre, University of TorontoToronto, OntarioCanada
  3. 3.Department of Clinical BiochemistryUniversity of TorontoToronto, OntarioCanada

Personalised recommendations